Literature DB >> 21878895

Thyroid cancer: finding the malignant thyroid nodule in the haystack.

Kristien Boelaert, Christopher J McCabe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21878895     DOI： 10.1038/nrendo.2011.152

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations.

Authors:  H Gharib; E Papini; R Paschke; D S Duick; R Valcavi; L Hegedüs; P Vitti
Journal:  J Endocrinol Invest       Date:  2010       Impact factor: 4.256

Review 2.  Clinical practice. The thyroid nodule.

Authors:  Laszlo Hegedüs
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

Review 3.  Biomarker panel diagnosis of thyroid cancer: a critical review.

Authors:  Obi L Griffith; Connie G Chiu; Allen M Gown; Steven J M Jones; Sam M Wiseman
Journal:  Expert Rev Anticancer Ther       Date:  2008-09       Impact factor: 4.512

4.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

5.  Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and Galectin-3 expression on liquid-based fine-needle cytology.

Authors:  Guido Fadda; Esther Diana Rossi; Marco Raffaelli; Alfredo Pontecorvi; Stefano Sioletic; Francesca Morassi; Celestino Pio Lombardi; Gian Franco Zannoni; Guido Rindi
Journal:  Eur J Endocrinol       Date:  2011-07-01       Impact factor: 6.664

6.  Immunohistochemical diagnosis of papillary thyroid carcinoma.

Authors:  C C Cheung; S Ezzat; J L Freeman; I B Rosen; S L Asa
Journal:  Mod Pathol       Date:  2001-04       Impact factor: 7.842

7.  A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior.

Authors:  Sonia Cheng; Stefano Serra; Moises Mercado; Shereen Ezzat; Sylvia L Asa
Journal:  Clin Cancer Res       Date:  2011-03-09       Impact factor: 12.531

8.  Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance".

Authors:  N Paul Ohori; Marina N Nikiforova; Karen E Schoedel; Shane O LeBeau; Steven P Hodak; Raja R Seethala; Sally E Carty; Jennifer B Ogilvie; Linwah Yip; Yuri E Nikiforov
Journal:  Cancer Cytopathol       Date:  2010-02-25       Impact factor: 5.284

9.  Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.

Authors:  Yuri E Nikiforov; David L Steward; Toni M Robinson-Smith; Bryan R Haugen; Joshua P Klopper; Zhaowen Zhu; James A Fagin; Mercedes Falciglia; Katherine Weber; Marina N Nikiforova
Journal:  J Clin Endocrinol Metab       Date:  2009-03-24       Impact factor: 5.958
  9 in total
  2 in total

1.  Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo.

Authors:  Emanuel Peplau; Francesco De Rose; Andreas Eichinger; Sybille Reder; Markus Mittelhäuser; Giorgia Scafetta; Markus Schwaiger; Wolfgang A Weber; Armando Bartolazzi; Calogero D'Alessandria; Arne Skerra
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

2.  Contrast-Enhanced CT-Based Radiomics for the Differentiation of Nodular Goiter from Papillary Thyroid Carcinoma in Thyroid Nodules.

Authors:  Zhenyu Li; Haiming Zhang; Wenying Chen; Hengguo Li
Journal:  Cancer Manag Res       Date:  2022-03-14       Impact factor: 3.989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.